[1] 丰涛,沈赞.三氧化二砷对骨肉瘤细胞株MG63/dox多药耐药的逆转作用及其机制[J].临床肿瘤学杂志,2016,21(1):6~11.
[2] 陈自强,张玮,李玉平,等.纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J].药学实践杂志,2016,34(2):103~105.
[3] Egorov D, Schwob L, Lalande M, et al. Near edge X-ray absorption mass spectrometry of gas phase proteins: the influence of protein size[J]. Physical Chemistry Chemical Physics Pccp, 2016, 18(37):26213.
[4] 郑铁钢,郭全义,陈继营,等.载多柔比星磁性纳米颗粒逆转人骨肉瘤细胞多药耐药性的实验研究[J].肿瘤研究与临床,2015,27(6):361~364.
[5] 李梦双,郭传龙,李君,等.多药耐药蛋白1和多药耐药相关蛋白5、7在糖尿病小鼠视网膜中表达的变化[J].眼科新进展,2017,37(1):10~14.
[6] Schennach M, Breuker K. Probing protein structure and folding in the gas phase by electron capture dissociation[J]. Journal of The American Society for Mass Spectrometry, 2015, 26(7):1059~1067.
[7] 孙振国,张治宇,王锋.骨肉瘤耐药性相关信号转导通路研究进展[J].医学综述,2017,23(3):488~491.
[8] van Zweeden A A, Hj V D V, Wilmink J W, et al. Phase I clinical trial to determine the feasibility and maximum tolerated dose of panitumumab to standard gemcitabine-based chemoradiation in locally advanced pancreatic cancer.[J]. Clinical Cancer Research,2015, 21(20):4569.
[9] 陈楷,吕书军,付东,等.骨肉瘤凋亡与耐药相关机制的研究进展[J].中国骨与关节杂志,2015,2(1):45~49.
[10] 符策岗,赵红卫,刘扬,等.骨肉瘤直接抑制化疗药物疗效的分子机制[J].海南医学,2015,3(1):70~73.
[11] Evens A M, Balasubramanian S, Vose J M, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma.[J]. Clinical Cancer Research, 2016, 22(5):1059.
[12] 张浩强,王臻,鲍莉,等.拷贝数变异对多发骨肉瘤临床分型与耐药机制的影响[J].中华骨科杂志,2015,35(4):442~449.
[13] 吴宏增,王进,冯和林.自噬与骨肉瘤的研究进展[J].肿瘤防治研究,2017,44(2):153~156.
[14] 尤龙飞,丁木亮,倪江东.lncRNA在骨肉瘤中的研究进展[J].医学临床研究,2016,33(10):1993~1997.
[15] 侯晓,李纯璞,陈元振,等.Notch通路在骨肉瘤发病机制中的研究现状[J].中国矫形外科杂志,2015,23(9):804~807. |
2018, Vol. 24 
